Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Head and Neck Surgery

Cancer Immunotherapy 102

Monday, October 2, 2023
9:15 AM - 10:15 AM East Coast USA Time
Location: Ballroom C2

    Moderator(s)

  • LS

    Larissa Sweeny, MD

    Associate Professor, Otolaryngology - Head and Neck Surgery
    University of Miami Health System
    Miami, FL, United States

    • Panelist(s)

  • Joseph M. Curry, MD

    Professor
    Thomas Jefferson University Hospital
    Wynnewood, PA, United States

  • Rajarsi Mandal, MD

    Assistant Professor
    Northwell Health-Hofstra Zucker School of Medicine
    Baltimore, MD, USA

  • R. Bryan Bell, MD

    Physician Executive Director, Division of Surgical Oncology, Radiation Oncology & Clinical Programs
    Providence Cancer Institute; Earle A. Chiles Research Institute
    Portland, OR, OR, United States

Disclosure(s):
Larissa Sweeny, MD: No relevant relationships to disclose.
R. Bryan Bell, MD: No relevant relationships to disclose.
PROGRAM DESCRIPTION: This is the second part of the popular course, previously named Immunotherapy for Cancer: What the Otolaryngologist needs to Know. In recent years immunotherapy has shown promise as a new therapeutic pathway for the treatment of head and neck cancer. The second part of this course will focus on emerging biomarkers in oncology, ongoing clinical trials and exciting future directions for the field. Understanding the current state and future directions of immunotherapy is valuable for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an in-depth review of biomarkers, ongoing clinical trials, and potential future agents.

OUTCOME OBJECTIVE 1: Upon completion of this activity, the participants should have an understanding of new and emerging biomarkers for HNC.

OUTCOME OBJECTIVE 2: Upon completion of this activity, the participants should have an understanding of ongoing clinical trials evaluating immunotherapies for treatment of HNC.

OUTCOME OBJECTIVE 3: Upon completion of this activity, the participants should have an understanding of new and emerging immunotherapies for HNC.

BACKGROUND STATEMENT: The field of immunotherapy is evolving rapidly. The general otolaryngologist and sub-specialist are getting inquiries from patients regarding these therapies. Staying up-to-date on the current as well as future therapies is imperative.